Jiangxi Institute of Biological Products Inc. (Ticker: 6915 HK) is a China-domiciled biotechnology company that develops, manufactures and sells human tetanus antitoxin products. Human tetanus antitoxin is an antibody-based treatment used to provide immediate protection or treatment after possible tetanus exposure by neutralizing the toxin that causes the disease. The company also produces antiserum vial and ampoule preparations and markets its products in China, the Philippines, Egypt and other countries.

Jiangxi Institute of Biological Products is expected to list H shares on the Hong Kong Stock Exchange on June 30, 2026, with pricing expected on June 26, 2026. The company plans to offer 36.23 million shares at an expected price range of HKD 9.33 to HKD 13.06 per share, raising up to approximately HKD 473 million, or approximately $60 million. The offering consists entirely of primary shares and includes a 15% greenshoe option.

According to Frost & Sullivan, the company was the largest human tetanus antitoxin provider in China and globally by sales volume in 2025. Joint managers include Arta Asset Management, CMBC Securities, CICC and China Merchants-related syndicate members.